



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Dist. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date:14/11/2017

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
--	--

Sub: Approval of Un Audited Financial Result for the quarter and six months ended on 30th September,2017 and Limited Review Report thereon and Statement of Assets and Liabilities for the half year ended on 30th September 2017.

Ref: Scripe Code: 524396; Sripe Id: BIOFILCHEM; ISIN: INE829A01014

Dear Sir/Madam

With reference to the above-mentioned subject in meeting of the Board of the Directors of the Company held on today, has approved the Un Audited Financial Result for the quarter ended on 30th September ,2017 and Limited Review Report thereon and Statement of Assets and Liabilities for the half year ended on 30th September 2017.

Copy of audited financial result along with Limited Review Report is enclosed with this letter and copy of the same is also available on website of the Company. i.e www.biofilgroup.net

This is for your information and record.

Thanking you,

Yours Faithfully

For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director
DIN :- 00028819





Limited Review Report

**The Board of Directors,
M/S Biofil Chemicals And Pharmaceuticals Limited
11/12, Sector E Sanwer Road
Industrial Area
Indore452015 -M.P.**

We have reviewed the accompanying statement of unaudited financial results (the "Statement") of Biofil Chemicals and Pharmaceuticals Limited ("the Company") for the quarter ended 30th September 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with CIR/CFD/FAC/62/2016 dated 5th July 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, SEBI Circular CIF/CFD/CMD/15/2015 dated 30th November 2015, and CIR/CFD/FAC/62/2016 dated 5th July 2016, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MAHESHWARI & GUPTA
Chartered Accountants
FRN : 061792

CA. SUNIL MAHESHWARI
Partner
M.NO. 403346

Date: 14.11.2017
Place: Indore

Un-Audited Financial Results of Quarter and Half Year Ended of Sep . 2017

M/s. Biofil Chemicals & Pharmaceuticals Limited


11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

UN- AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th Sept , 2017

(Amount in Lakhs except EPS)

Statement of Standalone Unaudited Financial Results for the Quarter & Half Year ended 30th Sep 2017							
Particulars	Quarter Ended			Half Year Ended		Audited for the year ended March 31 2017	
	3 months ended (30/09/2017)	Preceding 3 months ended (30/06/2017)	Corresponding 3 months ended in the previous year (30/09/2016)	Year to date figures for current period ended (30/09/2017)	Year to date figures for the previous year ended (30/09/2016)		
	Un- audited	Un- audited	Un- audited	Un- audited	Un-audited	Audited	
I	Revenue from Operation	83.36	706.35	292.45	789.71	324.24	1347.74
II	Other Income	0.70	0.32	3.45	1.02	4.58	11.49
III	Total Revenue (I + II)	84.05	706.67	295.90	790.72	328.82	1359.23
IV	Expenses						
	(a) Cost of materials consumed	12.20	13.52	13.68	25.73	30.87	90.41
	(b) Purchases of stock-in-trade	35.05	663.75	172.60	698.80	177.40	762.02
	(c) Changes in inventories of finished goods, work-in-	(4.20)	(2.20)	6.42	(6.40)	(4.83)	(1.32)
	(d) Employee benefits expense	17.33	5.69	10.54	23.02	15.11	53.22
	(e) Finance Cost	3.86	3.75	3.75	7.61	7.50	16.36
	(f) Depreciation and Amortisation Expense	7.11	7.11	6.53	14.22	13.06	28.42
	(g) Other expenses	5.49	5.28	54.98	10.77	59.80	179.08
	Total expenses	76.85	696.91	268.51	773.75	298.91	1128.19
V	Profit (Loss) before exceptional items and tax (III-IV)	7.21	9.76	27.39	16.97	29.91	231.04
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit (Loss) before tax (V - VI)	7.21	9.76	27.39	16.97	29.91	231.04
VIII	Tax expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	51.62
	(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operation VII-VIII)	7.21	9.76	27.39	16.97	29.91	179.42
X	Profit (Loss) for the period for dis-continued operation	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit (Loss) for the period for dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit (Loss) for the period (IX+XII)	7.21	9.76	27.39	16.97	29.91	179.42
XIV	Other Comprehensive Income						
	A) (I) Items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B) (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	c) Other Comprehensive Income (net of tax) 6a± 6b)	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV)	7.21	9.76	27.39	16.97	29.91	179.42
XVI	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XVII	Other Equity excluding Revaluation Reserve as per balance Sheet			0.00			376.21
XVIII	Earnings per equity shares:			0.00			
	(1) Basic (Rs)	0.044	0.060	0.168	0.104	0.184	1.102
	(2) Diluted (Rs)	0.044	0.060	0.168	0.104	0.184	1.102



1. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2016.

2. The standalone unaudited financial results of Biofil Chemicals & Pharmaceuticals Ltd, ("the company" for the quarter ended September 30, 2017 were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on November 14, 2017.

3. The Limited Review of the financial Results of the Quarter ended 30th September 2017 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015, has been carried out by the Statutory Auditors.

4. The Ind AS compliant corresponding figures for the quarter ended September 30 2016, have not been subject to review or audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of the its affairs.

5. The Company has reported segment wise information as per Accounting Standard (AS-17). The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

1. Pharma Product
2. Chemicals Division
3. Plastic Division

6. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below.

Particulars	Quarter Ended	Half Year Ended
	Sep 30 , 2016	Sep 30 , 2016
	Reviewed	Reviewed
	30.09.2016	30.09.2016
Total Income / Revenue From Operations	292.45	324.24
Net Profit for the period before tax (before Exceptional and/or Extraordinary items)	27.39	29.91
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	27.39	29.91
Net Profit for the period after tax	27.39	29.91
Total Comprehensive Income for the period {Comprising Profit for the period after Tax and Other	27.39	29.91
Paid up Equity Share Capital	1627.38	1627.38
Earning Per Share in Rs. (Per Share of Rs. 10 each, Basic &	0.168	0.184
Basic	0.168	0.184
Diluted		

7. The aforesaid audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors

Date : 14/11/2017
Place : Indore

FOR Biofil Chemicals & Pharmaceuticals Limited


RAMESH SHAH
MANAGING DIRECTOR
(DIN : 00028819)



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
CIN NO. L24233MP1985PLC002709


Segmentwise Revenue, Results an Capital Employed for year ended 30th Sept 2017

(Amount in Lakhs)

S.No.	Segment Revenue	Quarter Ended			Half Year Ended		31 March 2017
		Sep 30 , 2017	June 30 , 2017	Sep 30 , 2016	Sep 30 , 2017	Sep 30 , 2016	
		Reviewed 30.09.2017	Reviewed 30-06-2017	Reviewed 30.09.2016	Reviewed 30.09.2017	Reviewed 30.09.2016	
1	Segment Revenue						
	Pharma Unit	36.22	679.30	179.36	715.52	185.52	1205.08
	Chemicals Division	47.14	24.21	34.12	71.35	59.75	139.077
	Plastic Division	0.00	2.84	0.00	2.84	0.00	1.281
	Other	0.70	0.32	82.42	1.02	83.55	13.794
	Gross Turnover	84.05	706.67	295.89	790.72	328.82	1359.23
2	Segment Results						
	Pharma Unit	1.52	15.71	35.09	17.23	39.53	252.24
	Chemicals Division	13.19	(1.29)	2.28	11.90	7.81	(21.46)
	Plastic Division	(3.75)	(0.91)	(6.24)	(4.66)	(9.92)	(7.26)
	Other		0.00	0.00	0.00	0	19.84
	Total Segment Profit Before Tax	10.96	13.51	31.14	24.47	37.42	243.36
	Interest Income		0.00		0.00		2.69
	Interest Expenses	3.75	3.75	3.75	7.50	7.50	15.01
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	7.21	9.76	27.39	16.97	29.92	231.04
	Provision for current tax	0	0.000				50.00
	Item Related Earlier Year	0	0.000				1.622
	Profit After Tax	7.21	9.76	27.39	16.97	29.92	179.42
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	1,814.50	1896.85	808.74	1,814.50	808.74	1309.64
	Chemicals Division	836.44	806.17	768.83	836.44	768.83	802.50
	Plastic Division	67.88	70.47	81.08	67.88	81.08	71.90
	Other		-				-
	Total (A)	2718.81	2773.50	1658.65	2718.81	1658.65	2184.04
	Segment Liabilities (B)						
	Pharma Division	1267.78	1299.62	407.44	1,267.78	407.44	703.01
	Chemicals Division	55.95	77.41	37.75	55.95	37.75	66.53
	Plastic Division	148.86	145.51	148.94	148.86	148.94	144.85
	Other				0.00		
	Total (B)	1472.59	1522.54	594.13	1472.59	594.13	914.38
	Total Capital Employed	1246.22	1250.96	1064.52	1246.22	1064.52	1269.65

DATE : 14-11-2017
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.


RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819



BIOFIL CHEMICALS & PHARMACEUTICALS Ltd.
UN-AUDITED FINANCIAL STATEMENT OF ASSETS AND LIABILITIES AS AT 30-09-2017
CIN NO. L24233MP1985PLC002709

(Rs. In Lacs)

Standalone Statement of Assets and Liabilities		Unaudited	Audited
Particulars		As at 31/09/2017	As at 31/03/2017
A	ASSETS		
1	Non-current assets:		
	(a) Property, Plant & Equipment	937.69	916.45
	(b) Capital work in Progress		
	(c) Other Intangible Assets		
	(d) Financial Assets:		
	i. Investments		
	ii. Other Financial Assets		
	(e) Other Non- Current Assets		
	Sub-total - Non-current assets	937.69	916.45
2	Current assets		
	(a) Inventories Current investments	10.23	16.63
	(b) Financial Assets:		
	(i) Trade receivables	1,665.66	1,146.44
	(ii) Cash and cash equivalents	19.57	7.48
	(iii) Bank balances other than (ii) above	9.18	23.49
	(iv) Loans	27.54	44.80
	(v) Other Financial Assets		
	(c) Current Tax Assest (Net)		
	(d) other Currents Assets	30.92	28.75
	(e) Assets classified as held for sale		
	Sub-total - Current assets		
	TOTAL - ASSETS	2,700.79	2,184.04
B	EQUITY AND LIABILITIES		
1	Equity		
	(i) Equity Share Capital	1627.38	1627.38
	(ii) Other Entity	(340.76)	(357.73)
	Sub-total- Equity	1286.62	1269.65
2	Non-current Liabilities :		
a	Financial Liabilities		
	(i) Borrowings		
	(ii) other Financial Liabilities		
b	Provisions		
c	Deferred tax liabilities (net)		
d	Other Non-current Liabilities		
	Sub-total - Non-current liabilities	1286.62	1269.65
3	Current liabilities		
a	Financial Liabilities		
	(i) Borrowings	149.56	142.81
	(ii) Trade Payables	1211.86	709.52
	(iii) other Financial Liabilities		
b	Other Current Liabilities		
c	Provisions	52.75	62.05
d	Current Tax Liabilities (Net)		
	Sub-total - Current liabilities	1,414.17	914.38
	TOTAL - EQUITY AND LIABILITIES	2,700.79	2,184.04

Date : 14/11/2017
Place : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

RAMESH SHAH
MANAGING DIRECTOR
(DIN NO. 00028819)

